Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

기사 요약

Rocket Pharmaceuticals announces positive early safety results for its RP-A501 Phase 2 trial in Danon disease and plans further FDA talks.